Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring
- 1 December 2019
- journal article
- research article
- Published by Elsevier BV in Genetics in Medicine
- Vol. 21 (12), 2686-2694
- https://doi.org/10.1038/s41436-019-0561-7
Abstract
No abstract availableKeywords
Funding Information
- Valerion Therapeutics (not applicable)
This publication has 36 references indexed in Scilit:
- Cardiac Pathology in Glycogen Storage Disease Type IIIPublished by Springer Science and Business Media LLC ,2012
- Characterization of a canine model of glycogen storage disease type IIIaDisease Models & Mechanisms, 2012
- Markedly Elevated Serum Transaminases in Glycogen Storage Disease Type IIIJournal of Pediatric Gastroenterology and Nutrition, 2011
- Elevated serum biotinidase activity in hepatic glycogen storage disorders–A convenient biomarkerJournal of Inherited Metabolic Disease, 2007
- Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?Journal of Hepatology, 2006
- Molecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and TurkeyJournal of Human Genetics, 2006
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis CHepatology, 2003
- Fatal Liver Cirrhosis and Esophageal Variceal Hemorrhage in a Patient with Type IIIa Glycogen Storage Disease.Internal Medicine, 1998
- Type IIIb glycogen storage disease associated with end-stage cirrhosis and hepatocellular carcinomaHepatology, 1997